Xeris Biopharma (XERS) said Monday that the US Food and Drug Administration has approved the company's supplemental new drug application for Gvoke VialDx for use as a diagnostic aid to temporarily inhibit gastrointestinal tract movement during radiologic examinations in adult patients.
Xeris also said it has partnered with American Regent to commercialize Gvoke VialDx in the US.
Xeris said it would handle product supply while American Regent would oversee commercialization.
Financial terms of the agreement were not disclosed.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。